Evidence continues to grow that KRAS, once considered an “undruggable” target, can be targeted successfully in non–small cell lung cancer. In a phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.